Target enrichment as a pre-sequencing DNA preparation method is invaluable for clinical and industrial applications where accuracy, cost-effectiveness, and throughput are critical. As a leader in hybridization-based target enrichment, Agilent’s SureSelect sequencing panels are highly sensitive and enable detection of single-nucleotide, structural, and copy number variants, fusions, insertions, and deletions.

Element’s avidity sequencing technology offers enhanced contrast-to-noise ratio (CNR) and inherent error suppression mechanism to produce scarless DNA products. The collaboration between the two companies demonstrates that Element’s technology can be seamlessly integrated into Agilent’s target enrichment technology.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets.